Drug Trial Radar · NCT01393132
Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
Last checked: Nov 19, 2026Latest source record: Dec 23, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Mar 2011
Primary completion
Dec 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- Michigan Cornea Consultants, PCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kresge Eye Institute
- First posted
- Jul 13, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Severe dry eye is a debilitating ocular disease resulting in loss of vision, reduced day-to-day function and significant discomfort. Tear substitutes are an important part of the treatment of all patients, however, even with aggressive us, the corneal(ocular)surface often remains very irregular due to poor surface healing. The agent being evaluated in this study, Thymosin Beta 4, promotes healing of the corneal surface and has been studied in patients with recalcitrant corneal ulcers and erosions with significant success (Arch Ophthalmol. 2010;128(5):636-638., Ann of the NY Acad of Sci, May, 2010). The study hypothesis is that Thymosin Beta 4, in its role as a modulator of corneal surface healing, may be able to promote healing of the corneal surface allowing for more conventional modalities to take over and maintain a smooth and regular ocular surface. The investigators hope to be able to demonstrate an improvement in visual acuity, surface healing and a reduction in dry-eye related symptoms.
Conditions
- Dry Eye
- Sjogren's Syndrome
- Graft vs. Host Disease
Interventions
Thymosin Beta 4 eye dropsDrug
Patients will be randomized and will receive the same eye drops the Thymosin Beta 4.
Vehicle ControlDrug
Patients will be randomized and will receive the same eye drops without the Thymosin Beta 4.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SafetyTime frame: Day 1, Day 14, Day 28 and Day 56
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Michigan Cornea Consultants, P.C.
Southfield, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.